INFLAMMATION and VASCULAR FUNCTION in ACUTE STROKE and TIA: TREATMENT WITH ATORVASTATIN and IRBESARTA

Phase 4

• Conditions: Acute Ischaemic Stroke; Transient Ischaemic Attack; Stroke - Ischaemic

• Registration Number: ACTRN12605000175673
• Lead Sponsor: niversity of Western Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients presenting to facilities of the North Metropolitan Area Health Service within 10 days of acute ischaemic stroke.

Exclusion Criteria

Finger prick or laboratory blood sugar level > 13 mmol/L at baseline; - Acute co morbid condition (such as myocardial ischaemia or sepsis); - Pre-menopausal female; - Haemorrhage seen on initial CT.Statin exclusion criteria: - History of sensitivity to statins; - Active liver disease or unexplained elevation in transaminasesIrbesartan exclusion criteria: - Hypotension (SBP< 100mmHg or DBP<70mmHg); - Hypertension (>220 mmHg) or clinical imperative to lower blood pressure hyperkalaemia: >5.5 mmol/L; - History of sensitivity to ATRA; - Renal impairment (defined as creatinine >120 umol/L); - Current treatment with an ATRA or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified